Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Dongyuan, Xing"'
Autor:
Sami Diab, Vassiliki Karantza, Ella Kleynerman, Dongyuan Xing, Claudio Savulsky, Grace Wang, Yuan Yuan, Debra A. Patt, Eleni Andreopoulou, Sharon T. Wilks, Peter A. Kaufman, Ruth M. O'Regan, Michaela L. Tsai, Gursel Aktan, David R. D'Adamo, Virginia G. Kaklamani, Kevin Kalinsky, Sara M. Tolaney
Purpose:As monotherapies, eribulin (chemotherapy) and pembrolizumab (immunotherapy) have shown promise for patients with metastatic triple-negative breast cancer (mTNBC). This phase Ib/II study examined eribulin plus pembrolizumab as a potential mTNB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::703b5a9c0f4a055b8338f260ccadb13b
https://doi.org/10.1158/1078-0432.c.6530040.v1
https://doi.org/10.1158/1078-0432.c.6530040.v1
Autor:
Sami Diab, Vassiliki Karantza, Ella Kleynerman, Dongyuan Xing, Claudio Savulsky, Grace Wang, Yuan Yuan, Debra A. Patt, Eleni Andreopoulou, Sharon T. Wilks, Peter A. Kaufman, Ruth M. O'Regan, Michaela L. Tsai, Gursel Aktan, David R. D'Adamo, Virginia G. Kaklamani, Kevin Kalinsky, Sara M. Tolaney
Supplementary Information
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2651cad31791dcbd5d9c34941f502a4e
https://doi.org/10.1158/1078-0432.22478769.v1
https://doi.org/10.1158/1078-0432.22478769.v1
Autor:
Francine M. Foss, Youn H. Kim, H. Miles Miles Prince, Timothy M. Kuzel, Costas K. Yannakou, Chean Eng Ooi, Dongyuan Xing, Nicholas Sauter, Preeti Singh, Myron Czuczman, Madeleine Duvic
Publikováno v:
Blood. 140:1491-1492
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adb9a6b180f56611fbafb801ac4158f0
https://doi.org/10.1182/blood-2022-166916
https://doi.org/10.1182/blood-2022-166916
Autor:
H. Miles Miles Prince, Larisa J Geskin, Oleg E Akilov, Timothy M. Kuzel, Christiane Querfeld, Chean Eng Ooi, Dongyuan Xing, Nicholas Sauter, Preeti Singh, Myron Czuczman, Francine M. Foss
Publikováno v:
Blood. 140:6577-6578
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3a52f7aa4b90bd553d12ba12137563f
https://doi.org/10.1182/blood-2022-167564
https://doi.org/10.1182/blood-2022-167564
Autor:
Tomas Buchler, Pablo Maroto, Sun Young Rha, Thomas Powles, Toni K. Choueiri, Viktor Grünwald, M.J. Méndez-Vidal, Karla Rodriguez-Lopez, S-H. Hong, Camillo Porta, Eric Winquist, Thomas E. Hutson, Masatoshi Eto, Robert J. Motzer, Evgeny Kopyltsov, Jeffrey C. Goh, Alan D. Smith, T. Takagi, Dongyuan Xing
Publikováno v:
Annals of Oncology. 32:S683-S685
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f88be990ae1ccafedc9a09544eb8e81c
https://doi.org/10.1016/j.annonc.2021.08.056
https://doi.org/10.1016/j.annonc.2021.08.056
Autor:
Martin H Voss, Thomas Powles, Bradley Alexander McGregor, Camillo Porta, Viktor Grünwald, Jaime R. Merchan, Frederic Rolland, Pablo Maroto-Rey, Jeffrey C. Goh, Dongyuan Xing, Rodolfo F. Perini, Jodi McKenzie, Kalgi Mody, Robert J. Motzer
4514 Background: In the open-label, randomized, phase 3 CLEAR study, LEN + PEMBRO had significant PFS (primary endpoint) and OS (key secondary endpoint) benefits over SUN among pts with aRCC in the 1L setting (Motzer 2021, NEJM). We evaluated PFS on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99be977d323d515219a0a8a665e88f5a
Publikováno v:
ICAIIS
With the development of optical communication technology, it's application was more and more extensive. Researchers had proposed a new type of optical communication technology, which connected the high-speed internet wire device to LED lighting devic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2f6fd3bd61fdd3db50b7ffa61775be2
https://doi.org/10.1145/3469213.3470682
https://doi.org/10.1145/3469213.3470682
Autor:
Sun Young Rha, Thomas Powles, Boris Alekseev, Evgeny Kopyltsov, Rodolfo F. Perini, Jeffrey C. Goh, Jaime R. Merchan, Robert J. Motzer, Thomas E. Hutson, Alan D. Smith, Masatoshi Eto, Teresa Alonso Gordoa, Camillo Porta, Sung-Hoo Hong, María José Méndez Vidal, Anil Kapoor, Toni K. Choueiri, Dongyuan Xing, Viktor Grünwald, Kalgi Mody
269 Background: In pts with advanced RCC, second-line treatment with LEN + EVE prolonged progression-free survival (PFS) compared with EVE alone. LEN + PEMBRO, also showed preliminary efficacious evidence in a phase 1/2 RCC study. Here, we describe t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3afdbde8a5b67558d77f16a759fabc3a
Autor:
Peter A. Kaufman, Ella Kleynerman, Claudio Savulsky, Virginia G. Kaklamani, Sharon Wilks, Michaela L. Tsai, Grace Wang, Yuan Yuan, Dongyuan Xing, D. R. D'Adamo, Gursel Aktan, Eleni Andreopoulou, Debra A. Patt, Ruth O'Regan, Sara M. Tolaney, Sami Diab, Kevin Kalinsky, Vassiliki Karantza
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(11)
Purpose: As monotherapies, eribulin (chemotherapy) and pembrolizumab (immunotherapy) have shown promise for patients with metastatic triple-negative breast cancer (mTNBC). This phase Ib/II study examined eribulin plus pembrolizumab as a potential mTN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d18ff08c7305436447d9f5e35e7471a1
https://pubmed.ncbi.nlm.nih.gov/33727258
https://pubmed.ncbi.nlm.nih.gov/33727258
Autor:
Karla Rodriguez-Lopez, Lea Dutta, Howard Gurney, Thomas E. Hutson, Avivit Peer, Robert J. Motzer, Dongyuan Xing, Masatoshi Eto, Anna Alyasova, Hilary Glen, Sun Young Rha, Thomas Powles, Viktor Grünwald, Camillo Porta, Jaime R. Merchan, Toshio Takagi, Toni K. Choueiri, Manuela Schmidinger, Ulka N. Vaishampayan, Ugo De Giorgi
Publikováno v:
Journal of Clinical Oncology. 39:4562-4562
4562 Background: The multicenter, open-label, randomized, phase 3 CLEAR study showed that LEN + EVE had a significant PFS benefit (HR 0.65, 95% CI 0.53-0.80, P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4833dbdde1ed066a90e5968b3386a02b
https://doi.org/10.1200/jco.2021.39.15_suppl.4562
https://doi.org/10.1200/jco.2021.39.15_suppl.4562